Erythropoietin and fibronectin compositions for bone regneration
AssigneeRemedor Biomed Ltd.
InventorSaher HAMED
Life of this patent
Estimating the term…
Abstract
A method of promoting bone regeneration in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of Erythropoietin and Fibronectin, thereby promoting bone regeneration in the subject, (i) wherein the therapeutically effective amount of the Erythropoietin is selected from the group consisting of: about 1-50 mg/Kg for systemic administration; and about 0.1-50 mg/ml for local administration, and (ii) wherein the therapeutically effective amount of the Fibronectin is selected from the group consisting of: about 100-1000 mg/ml for systemic administration; and about 50-500 mg/ml for local administration.
Claims11
1-15. (canceled)
A method of treating a bone injury by promoting bone regeneration in a subject in need thereof, the method comprising administering to the patient a composition comprising a therapeutically effective amount of Erythropoietin, Fibronectin, and platelet-derived growth factor, wherein,
- (i) said therapeutically effective amount of said Erythropoietin is:
- 1-50 μg/Kg for systemic administration;
- or
- 0.1-50 μg/ml for local administration;
- (ii) said therapeutically effective amount of said Fibronectin is:
- 100-1000 μg/ml for systemic administration;
- or
- 50-500 μg/ml for local administration;
- and
- (iii) said therapeutically effective amount of said platelet-derived growth factor is:
- 10-100 ng/ml for systemic administration;
- or
- 1-50 ng/ml for local administration.
Dependencies are inferred from the claim text.